Novartis reports positive Phase III REMODEL-1/-2 data for remibrutinib in relapsing multiple sclerosis
NVS•Novartis reported positive Phase III REMODEL-1/-2 data for remibrutinib in relapsing multiple sclerosis; late-breaking results are scheduled for presentation at MSToronto2026 on Oct. 23.
1. Conference presentations
Novartis said late-breaking Phase III data from REMODEL-1/-2 will be presented at MSToronto2026 on Oct. 23, describing remibrutinib as a potential new oral BTK inhibitor option for relapsing multiple sclerosis. Separate late-breaking Phase III NEOS findings on Kesimpta in pediatric multiple sclerosis and additional Kesimpta presentations are also scheduled, and the company plans a virtual investor event to discuss the REMODEL readout.
